| Literature DB >> 34178979 |
Talita Baptista1, Lucas Araújo de Azeredo1, Aline Zaparte1, Thiago Wendt Viola1, Sayra Catalina Coral1, Maria Aparecida Nagai2,3, Flávia Rotea Mangone3, Ana Carolina Pavanelli3, Jaqueline B Schuch4, Victor Mardini4,5, Claudia M Szobot4,5, Rodrigo Grassi-Oliveira1,6.
Abstract
BACKGROUND: Prenatal cocaine exposure (PCE) is associated with behavioral, cognitive, and social consequences in children that might persist into later development. However, there are still few data concerning epigenetic mechanisms associated with the effects of gestational cocaine exposure, particularly in human newborns. AIMS: We investigated the effects of PCE on DNA methylation patterns of the Oxytocin Receptor (OXTR) gene in the umbilical cord blood (UCB). The relationship between UCB DNA methylation levels and the severity of the mother's cocaine use during pregnancy was also evaluated.Entities:
Keywords: OXTR; cocaine; epigenetic; newborn; pregnancy; prenatal; pyrosequencing; substance use disorders
Year: 2021 PMID: 34178979 PMCID: PMC8220805 DOI: 10.3389/fcell.2021.639287
Source DB: PubMed Journal: Front Cell Dev Biol ISSN: 2296-634X
FIGURE 1Schematic view of the oxytocin receptor gene (OXTR) located at chromosome 3p25, nt 8,809,533–8,809,566. CpG sites within the target sequence analyzed after sequencing are underlined and numbered consecutively. Sites 1–9 indicate the CpG position analyzed by commercial assays, OXTR1 (PM00016821) and OXTR2 (PM00016828).
Sociodemographic and clinical characteristics of pregnant crack cocaine users and their newborns in comparison to a control group.
| Ethnicity | ||||||
| Caucasians | 19 (63.3%) | 14 (46.7%) | 1 | 0.194 | 0.50 (0.18–1.42) | |
| Others | 11 (36.7%) | 16 (53.3%) | ||||
| Apgar, 1 min | 8.60 ± 1.37 | 8.48 ± 0.65 | 56 | 0.684 | 0.96 | |
| Apgar, 5 min | 9.63 ± 0.55 | 9.33 ± 0.63 | 56 | 0.059 | 0.94 | |
| Weight, kg | 3.10 ± 0.4 | 4.35 ± 0.8 | 57 | 0.391 | 1.90 | |
| Male sex, | 16 (53.3%) | 8 (26.7%) | 0.43 (0.21–1.16) | |||
| Age, years | 26.97 ± 6.18 | 27.29 (± 6.18) | 0.20 | |||
| Ethnicity | ||||||
| Caucasians | 23 (76.7%) | 9 (23.3%) | 1 | 4.92 (1.61–15.07) | ||
| Others | 7 (40.0%) | 18 (60.0%) | ||||
| Education | ||||||
| Up to secondary | 14 (46.7%) | 24 (82.8%) | ||||
| Above secondary | 16 (53.3%) | 5 (17.2%) | 5.48 (1.65–18.23) | |||
| Prenatal care | 30 (100%) | 20 (69.0%) | 1.45 (1.13–1.85) | |||
| Socioeconomic status | ||||||
| High | 8 (26.7%) | 2 (6.7%) | 5.09 (0.98–26.43) | |||
| Low | 22 (73.3%) | 28 (93.3%) | ||||
| Any psychopathology (except alcohol and drugs) | 0 (0%) | 2 (6.7%) | 1.07 (0.97–1.17) | |||
Frequency of drug use by crack cocaine-using mothers.
| Nicotine (%) | 14 (48.2%) | 2 (6.7%) | 3 (10.0%) | 2 (7.4%) | 8 (27.7%) |
| Alcohol (%) | 3 (10.3%) | 6 (20.7%) | 4 (12.6%) | 1 (5.0%) | 15 (48.4%) |
| Cannabis (%) | 4 (13.3%) | 3 (10%) | 2 (6.7%) | 2 (6.7%) | 17 (60%) |
| Crack cocaine (%) | 11 (36.7%) | 15 (53.3%) | 3 (10%) | 1 (5.0%) | 0 (0%) |
DNA methylation levels in OXTR exon III in the umbilical cord blood of the prenatal cocaine-exposed and non-exposed newborns.
| OXTR1 met | 22.04 ± 21.54 | 19.08 ± 17.44 | 0.16 | |||
| OXTR2 met | 26.87 ± 21.87 | 22.05 ± 13.33 | 50 | 0.30 | ||
| OXTR overall | 24.14 ± 15.45 | 19.98 ± 13.23 | 56 | 0.27 |
Zero-order correlations.
| Apgar 1 (min) | – | |||||||||
| Apgar 5 (min) | 0.66** | – | ||||||||
| Children weight (g) | −0.23 | −43* | – | |||||||
| Maternal age (years) | 0.31 | 0.09 | −0.24 | – | ||||||
| ASSIST tobacco | 0.13 | 0.04 | 0.11 | 0.16 | – | |||||
| ASSIST alcohol | −0.01 | 0.10 | −0.13 | −0.08 | 0.06 | – | ||||
| ASSIST cannabis | 0.20 | 0.21 | −0.13 | −0.16 | 0.02 | −0.02 | – | |||
| ASSIST crack cocaine | −0.15 | −0.05 | 0.07 | −0.51 | −0.13 | 0.11 | −0.06 | – | ||
| OXTR1 methylation | −0.14 | −0.28 | 0.09 | 0.05 | −0.08 | −0.01 | −0.13 | 0.36* | – | |
| OXTR2 methylation | 0.19 | 0.22 | 0.04 | −0.11 | 0.24 | 0.20 | 0.19 | 0.01 | −0.12 | – |
FIGURE 2Relationship between levels (%) of OXTR1 methylation in PCE newborns and ASSIST scores for crack cocaine usage among mothers in the 3 months prior to delivery.